Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.
Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.
The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.
The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.